Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF)

March 2012

You'll hear about Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF).

Kalydeco (ivacaftor) is the first drug that treats the underlying genetic mutation that causes CF...not just its symptoms.

Unfortunately, it'll only help patients with a rare mutation that affects about 4% of CF patients...about 1200 people in the U.S.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote